Story excerpt provided by St. Louis Business Journal.
Written by Brian Feldt .
RiverVest Venture Partners, the Clayton-based venture capital firm that invests in the life sciences sector, is part of a $15 million startup deal for Ohio-based VentureMed Group.
VentureMed is developing an endovascular medical device for patients suffering from peripheral artery disease (PAD).
Endeavour Vision, a Swiss-based venture firm, led the round. It’s the first time RiverVest has put money into the startup. The new capital will be used to fund the startup’s clinical plan, which includes current and future trials in the U.S. and Europe
Click here to read the complete article.
Originally published August 16, 2017.